Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Insurance Restructuring or Co-pay Caps? Testing Nuanced Messages In Charged Pricing Debate

This article was originally published in RPM Report

Executive Summary

The drug pricing debate isn’t fun for anyone in the biopharma sector, but it isn’t likely to go away soon. A recent Center for American Progress event highlights the challenges of finding the right message in a sound-bite focused climate – but also the benefits of engaging directly with critics.

Advertisement

Related Content

Lilly, Anthem Singing Same Tune On Value-Based Pricing, Communication Policy
The Campaign Against Drug Pricing: Candidates Can Only Hope Voters React As Strongly As Wall Street

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS079944

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel